Donor reactions during DDAVP‐stimulated plasmapheresis

Donor exposure can be strikingly reduced for patients with classical hemophilia A and von Willebrand's disease when large volumes of potent cryoprecipitated AHF are prepared from donors following DDAVP (1‐deamino‐8‐D‐arginine vasopressin) stimulation and automated plasmapheresis—a procedure called “plasma exchange donation.” Although this procedure has been reported to be relatively safe for donors, data are limited. Accordingly, we studied 20 donors during 48 procedures using DDAVP (0.3 μg/kg IV) followed by 2–3 L plasma collection. Replacement fluid for each initial plasma exchange donation was plasma protein fraction; autologous cryoprecipitate‐poor plasma was used for subsequent procedures. Mild reactions, particularly facial flushing, were noted in all 48 procedures. No procedure was discontinued, but four were modified due to either an increased pulse rate (≤20/min from baseline) or a fall in systolic or diastolic blood pressure (≤20 mm Hg from baseline). No donor was deferred or withdrew from the program. Based on our modest experience, DDAVP stimulated plasma exchange donation appears to be a safe and effective method for collecting large quantities of plasma from which potent cryoprecipitated AHF can be prepared. © 1992 Wiley‐Liss, Inc.

[1]  R. Strauss,et al.  Efficacy and safety of fenwal cs‐3000 plateletpheresis performed at a rapid donor blood flow rate: Rapid plateletpheresis with fenwal cs‐3000 , 1991, Journal of clinical apheresis.

[2]  B. Mcleod Myocardial infarction in a blood donor after administration of desmopressin , 1990, The Lancet.

[3]  J. Quinn,et al.  Severe hyponatremia after repeated intravenous administration of desmopressin , 1989, American journal of hematology.

[4]  R. Sassetti,et al.  Treatment of von willebrand's disease and hypofibrinogenemia with single donor cryoprecipitate from plasma exchange donation , 1989, American journal of hematology.

[5]  J. Gill,et al.  Hyponatremia and seizures in young children given ddavp , 1989, American journal of hematology.

[6]  D. Brettler,et al.  Factor concentrates for treatment of hemophilia: which one to choose? , 1989, Blood.

[7]  J. Scott,et al.  Simultaneous collection of platelets and cryoprecipitate by plasma‐exchange donation , 1989, Transfusion.

[8]  P. Mannucci Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. , 1988, Blood.

[9]  S. Albert,et al.  Venous thromboembolism and transient thrombocytopenia in a patient with diabetes insipidus treated with desmopressin acetate (DDAVP). , 1988, Thrombosis research.

[10]  J. Moake,et al.  Thrombosis following desmopressin for uremic bleeding , 1988, American journal of hematology.

[11]  J. Philippe,et al.  Myocardial infarction in a patient with hemophilia treated with DDAVP. , 1988 .

[12]  J. Scott,et al.  LONG TERM, FREQUENT PLASMA EXCHANGE DONATION OF CRYOPRECIPITATE , 1988, Thrombosis and Haemostasis.

[13]  M. Blombäck,et al.  DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. , 1987, Thrombosis research.

[14]  J. Scott,et al.  A high-potency, single-donor cryoprecipitate of known factor VIII content dispensed in vials. , 1987, Annals of internal medicine.

[15]  C. Kasper,et al.  Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. , 1985, Annals of internal medicine.

[16]  J. Scott,et al.  Use of 'single donor' factor VIII from plasma exchange donation. , 1984, JAMA.

[17]  M. Cheang,et al.  Improved hemophilia A carrier detection by DDAVP stimulation of factor VIII. , 1984, The Journal of pediatrics.